A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
The Methodist Hospital Research Institute
Mayo Clinic
M.D. Anderson Cancer Center
First Affiliated Hospital of Fujian Medical University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Halda Therapeutics OpCo, Inc.
University Hospital, Lille
Immuneering Corporation
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Immuneering Corporation
Imugene Limited
Opna Bio LLC
Nimbus Therapeutics
Essen Biotech
University of California, Davis
Icahn School of Medicine at Mount Sinai
Mural Oncology, Inc
ZielBio, Inc.
Aravive, Inc.
UNICANCER
QureBio Ltd.
University of Kansas Medical Center
Washington University School of Medicine
AIO-Studien-gGmbH
Tracon Pharmaceuticals Inc.
M.D. Anderson Cancer Center
Lumos Pharma
Acrotech Biopharma Inc.
Peking University
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Rochester
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
ChineseAMS
Ohio State University Comprehensive Cancer Center
University Hospital Tuebingen
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Celldex Therapeutics
Silence Therapeutics GmbH
Axcentua Pharmaceuticals AB
University of Chicago
ARCA Biopharma, Inc.